Bismarck News Updates

Hypothalamic Obesity Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

 Breaking News
  • No posts were found

Hypothalamic Obesity Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

December 11
07:00 2020
Hypothalamic Obesity Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

“Hypothalamic Obesity – Market Insights, Epidemiology, and Market Forecast-2030“

(Albany, US) DelveInsight has launched a new report on “Hypothalamic Obesity – Market Insights, Epidemiology, and Market Forecast-2030 

 

DelveInsight’s “Hypothalamic Obesity – Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Hypothalamic Obesity, historical and forecasted epidemiology as well as the Hypothalamic Obesity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some of the facts:

  • According to DelveInsight, the total prevalent population of Hypothalamic Obesity (HO) in the 7MM reported to be 20,663 in 2017.
  • Among the 7MM, the US had the highest prevalent cases of HO with 11,663 cases in 2017. Among the EU5 countries, Germany had the highest prevalent population of HO with 1656 cases, followed by UK and the France.
  • Spain had the lowest prevalent population of 972 in 2017.
  • As per our estimates, Japan had 2127 prevalent cases of HO in 2017.

 

Request for free sample report: https://www.delveinsight.com/sample-request/hypothalamic-obesity-market

 

Scope of the reports:

  • The report covers the descriptive overview of Hypothalamic Obesity, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Hypothalamic Obesity epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Hypothalamic Obesity are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Hypothalamic Obesity market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hypothalamic Obesity market

 

Request for free sample report: https://www.delveinsight.com/sample-request/hypothalamic-obesity-market

 

Hypothalamic obesity refers to obesity that is caused by physical or inborn damage to the hypothalamus. The hypothalamus is part of the brain that makes hormones that control specific body functions such as sleep, body temperature, and hunger. It also makes hormones that control other organs in the body, especially the pituitary gland.

The symptoms of hypothalamic obesity vary by the cause and include

  • Uncontrollable hunger
  • Rapid, excessive weight gain
  • Low metabolic rate.

If the pituitary gland is involved, symptoms may include small underdeveloped testes in males and delayed puberty. This condition most often occurs because of injury to the hypothalamus due to a tumor, swelling in the brain, brain surgery, or head trauma. The diagnosis is made by physical examination and review of the symptoms. There is no cure for hypothalamic obesity.  Treatment involves a combination of surgery, medications, and nutritional and lifestyle counselling.

 

Some of the Hypothalamic Obesity Companies Covered:

  • Saniona
  • Amylin Pharmaceuticals
  • AstraZeneca
  • And Many Others

 

Hypothalamic Obesity Drugs Covered:

  • Tesomet
  • Exenatide
  • And Many Others

 

Request for free sample report: https://www.delveinsight.com/sample-request/hypothalamic-obesity-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Hypothalamic Obesity

3. Competitive Intelligence Analysis for Hypothalamic Obesity

4. Hypothalamic Obesity: Market Overview at a Glance

4.1. Hypothalamic Obesity Total Market Share (%) Distribution in 2017

4.2. Hypothalamic Obesity Total Market Share (%) Distribution in 2030

5. Hypothalamic Obesity: Disease Background and Overview

6. Patient Journey

7. Hypothalamic Obesity Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Hypothalamic Obesity Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Hypothalamic Obesity: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Hypothalamic Obesity

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

Request for detailed TOC: https://www.delveinsight.com/sample-request/hypothalamic-obesity-market

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognised for its off-the-shelf syndicated market research reports as well as customised solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/hypothalamic-obesity-market

Categories